@inproceedings{inproceedings, title  = {{A randomised phase III multicentre trial to evaluate the duration of anti-PD1 monoclonal antibody monotherapy in patients with metastatic melanoma (DANTE) - Stage 1 Results}},

 url = {{}},

 year = {{2019}},

 month = {{1}},

 author = {{Danson S and Plummer R and Ottensmeier C and Hook J and Marshall H and Sagoo G and Meads D and Bestall J and Velikova G and Gallagher F and Smith A et al}},

 volume = {{121}},

 journal = {{BRITISH JOURNAL OF CANCER}},

 pages = {{23-23}},

 note = {{Accessed on 2025/01/03}}}